验证数据展示
| Neutralization |
产品信息
69013-1-Ig targets NeutraKine® IFN beta in ELISA, Neutralization applications and shows reactivity with Human samples.
| 经测试应用 | ELISA, Neutralization Application Description |
| 文献引用应用 | Neutralization |
| 经测试反应性 | Human |
| 文献引用反应性 | human, mouse |
| 免疫原 | human Humankine IFN beta protein HZ-1298 种属同源性预测 |
| 宿主/亚型 | Mouse / IgG1 |
| 抗体类别 | Monoclonal |
| 产品类型 | Antibody |
| 全称 | IFN beta |
| 别名 | Fibroblast interferon, IFB, IFF, IFN beta, IFNB, IFNB1, IFN-beta, Interferon beta, interferon, beta 1, fibroblast, NeutraKine® IFN beta |
| 基因名称 | IFN beta1 |
| Gene ID (NCBI) | 3456 |
| RRID | AB_2882931 |
| 偶联类型 | Unconjugated |
| 形式 | Lyophilized Powder |
| 纯化方式 | Protein G purification |
| 储存缓冲液 | Sterile PBS , pH 7.4 |
| 内毒素 | <0.1 EU/μg |
| 复溶 | This product was lyophilized from a 0.2 μm filtered solution in PBS. Reconstitute at 1.0 mg/mL in sterile H2O before use. |
| 稳定性与储存 | Lyophilized antibodies are stable for 1 year from the date of receipt if stored between (-20°C) and (-80°C). Upon reconstitution we recommend that the solution can be stored at (4°C) for short term or at (-20°C) to (-80°C) for long term. Repeated freeze thaw cycles should be avoided with reconstituted products. |
背景介绍
Interferon beta (IFN beta) is a cytokine that is naturally produced by the immune system in response to biological and chemical stimuli. It signals by binding to the heterodimeric type I IFN receptor composed of the IFNAR1 and IFNAR2 chains, and regulates the expression of a plethora of genes by means of the classical JAK/STAT and other pathways. Interferon beta (IFN beta) has been shown in several clinical trials to have efficacy in multiple sclerosis. Interferon beta gene therapy is expected to become widely available for clinical use in cancer patients, and this new strategy might be extended to molecular targeting therapy, or used in combination with cell therapy or other therapies.
This antibody can be used to neutralize the bioactivity of IFN beta.
发表文章
| Species | Application | Title |
|---|---|---|
Nat Commun Ebola virus VP35 hijacks the PKA-CREB1 pathway for replication and pathogenesis by AKIP1 association. | ||
Cell Rep Targeting TCF19 sensitizes MSI endometrial cancer to anti-PD-1 therapy by alleviating CD8+ T cell exhaustion via TRIM14-IFN-β axis |